« Modifying Red Blood Cells As Carriers |
| The Prospects of an Academic Job »
July 14, 2014
Targacept Fumbles the Bad News on Alzheimer's
Targacept has been working on some very hard therapeutic areas over the years, and coming up dry - dramatically so. They may have just done it again.
They've been testing TC-1734 in Alzheimer's over the last year or so, a partial agonist at nicotinergic receptors. That was a long-shot mechanism to start with, although to be sure, every Alzheimer's drug is a long-shot mechanism. This would be a stopgap compound even if it worked, like the existing acetylcholinesterase compound Donepezil.
And the company has apparently released the results of the clinical trial on its web site, inadvertently, you'd have to assume. The news first came out from BioRunUp on Twitter, and the text of the announcement was the the compound had failed to show superiority to Donepezil. The company has made no official announcement (as I write, anyway), and the press release itself appears to have been taken down a little while ago. But here's a screen shot, if you're interested. The stock (TRGT) has already reacted to the news, as you'd imagine it would, suddenly dropping like a brick starting at just before 2:30 PM EST. Not a good way to get the news out, that's for sure. . .
+ TrackBacks (0) | Category: Alzheimer's Disease | Clinical Trials
POST A COMMENT
- RELATED ENTRIES
- Thiola, Retrophin, Martin Shkrell, Reddit, and More
- The Most Unconscionable Drug Price Hike I Have Yet Seen
- Clinical Trial Fraud
- Grinding Up Your Reactions
- Peer Review, Up Close and Personal
- Google's Calico Moves Into Reality
- Reactive Groups: Still Not So Reactive
- A VC Firm Touts Its Successes - And Its Failures